Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.48 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.47 |
| ▸ | TGM2 | P21980 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 8/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | HINT1 | P49773 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27121433 | 0.90 | STING1 (0.45) | NT5ESTING1 | |
| SCHEMBL27112566 | 0.90 | STING1 (0.45) | NT5ESTING1 | |
| SCHEMBL22080175 | 0.89 | NT5E (0.49) | NT5EFUT5TGM2TAS1R3TAS1R1 | |
| SCHEMBL23542559 | 0.88 | STING1 (0.47) | NT5EFUT5STING1 | |
| SCHEMBL22080564 | 0.85 | NT5E (0.51) | NT5ETAS1R3TAS1R1P2RY2 | |
| SCHEMBL22080123 | 0.85 | NT5E (0.51) | NT5ETAS1R3TAS1R1P2RY2 | |
| SCHEMBL23476877 | 0.82 | NT5E (0.52) | NT5EFUT5TGM2TAS1R3TAS1R1 | |
| SCHEMBL20326926 | 0.82 | STING1 (0.48) | NT5ESTING1 | |
| SCHEMBL22080177 | 0.82 | NT5E (0.46) | NT5EFUT5TGM2TAS1R3TAS1R1 | |
| SCHEMBL24196674 | 0.82 | NT5E (0.52) | NT5EFUT5TGM2POLBKRAS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040053-B2 | Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling | CHINOOK THERAPEUTICS, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20200179431-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | Aduro Biotech, Inc. (US) | 2020-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179431-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING \"STIMULATOR OF INTERFERON GENE\" - DEPENDENT SIGNALLING | STING1, IRF3, CGAS | NT5E 115/4885FUT5 2144/4885TGM2 3598/4885 |
| US-11040053-B2 | Compositions and methods for activating “stimulator of interferon gene”13 dependent signalling | STING1, IRF3, CGAS | NT5E 144/4885FUT5 2255/4885TGM2 3872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.